First Survey of Metallo-β-Lactamase Producers in Clinical Isolates of Pseudomonas aeruginosa From a Referral Burn Center in Kurdistan Province.

BACKGROUND
Treatment of infectious diseases is becoming more challenging with each passing year. This is especially true for infections caused by Pseudomonas aeruginosa, an opportunistic pathogen with the ability to rapidly develop resistance to multiple classes of antibiotics.


OBJECTIVES
This study was conducted to determine the prevalence of metallo-β-lactamase (MBL)-producing strains among multidrug-resistant P. aeruginosa strains isolated from burn patients.


MATERIALS AND METHODS
The isolates were identified, tested for susceptibility to various antimicrobial agents, and screened for the presence of MβLs by using the double-disk synergy test. The minimal inhibitory concentration of imipenem was determined by microplate broth dilution method on Mueller-Hinton agar. To detect VIM, SIM, and GIM MBLs, the isolates were subjected to polymerase chain reaction.


RESULTS
In this study, we identified 100 P. aeruginosa isolates from 176 clinical specimens obtained from burn patients. The isolates showed maximum resistance to ampicillin (100%), ceftazidime (94%), and ceftriaxone (89%). The CLSI-MBL phenotypic test showed that of the 100 P. aeruginosa isolates, 22 (22%) were positive for MBL production in the double-disk synergy test. Of the 22 MBL-positive P. aeruginosa isolates, 8 were resistant to imipenem. PCR analysis showed that 8 isolates were positive for blaVIM1. The other genes blaSIM1 and blaGIM1 were not detected.


CONCLUSIONS
The study results demonstrate the serious therapeutic threat of the spread of MBL producers among P. aeruginosa populations. Metallo-β-lactamases were detected in 22% of imipenem-resistant P. aeruginosa isolates. Early detection and infection-control practices are the best antimicrobial strategies for this organism; therefore, systematic surveillance to detect MBL producers is necessary.

Background: Treatment of infectious diseases is becoming more challenging with each passing year. This is especially true for infections caused by Pseudomonas aeruginosa, an opportunistic pathogen with the ability to rapidly develop resistance to multiple classes of antibiotics.
Objective: This study was conducted to determine the prevalence of metallo-β-lactamase (MBL)-producing strains among multidrug-resistant P. aeruginosa strains isolated from burn patients.

Materials and Methods:
The isolates were identified, tested for susceptibility to various antimicrobial agents, and screened for the presence of MβLs by using the double-disk synergy test. The minimal inhibitory concentration of imipenem was determined by microplate broth dilution method on Mueller-Hinton agar. To detect VIM, SIM, and GIM MBLs, the isolates were subjected to polymerase chain reaction. Results: In this study, we identified 100 P. aeruginosa isolates from 176 clinical specimens obtained from burn patients. The isolates showed maximum resistance to ampicillin (100%), ceftazidime (94%), and ceftriaxone (89%). The CLSI-MBL phenotypic test showed that of the 100 P. aeruginosa isolates, 22 (22%) were positive for MBL production in the double-disk synergy test. Of the 22 MBL-positive P. aeruginosa isolates, 8 were resistant to imipenem. PCR analysis showed that 8 isolates were positive for blaVIM1. The other genes blaSIM1 and blaGIM1 were not detected.

Conclusion:
The study results demonstrate the serious therapeutic threat of the spread of MBL producers among P. aeruginosa populations. Metallo-β-lactamases were detected in 22% of imipenem-resistant P. aeruginosa isolates. Early detection and infection-control practices are the best antimicrobial strategies for this organism; therefore, systematic surveillance to detect MBL producers is necessary.

Implication for health policy/practice/research/medical education:
Pseudomonas aeruginosa, has showed up as a significant nosocomial pathogen particularly among burn patients. We have very scant information about the current state of Pseudomonas aeruginosa infections and their resistance pattern particularly ESBL. Moreover, with the increased use of prophylactic antibiotics to burn patients, careful surveillance of the changing trend of bacterial organisms and their antibiotic resistance pattern among neonates is warranted.

Background
Pseudomonas aeruginosa, a versatile pathogen associated with a broad spectrum of infections in humans and widely known as an opportunistic organism, is frequently involved in infections among susceptible populations, especially patients with burns (1). Furthermore, this organism possesses several virulence factors and is intrinsically resistant to most antimicrobials, a feature that is also responsible for the difficulty in treating infected patients (2). In the past decade, P. aeruginosa strains showing resistance to multiple β-lactam antibiotics, in particular, metallo-β-lactamase (MBL)-producing P. aeruginosa, have become an increasing public health problem worldwide (3)(4)(5). Furthermore, infection with MBLproducing organisms is associated with higher rates of mortality, morbidity, and health care costs (6)(7)(8).
In P. aeruginosa, resistance to extended-spectrum β-lactams is mediated by lack of drug penetration, which may occur due to porin mutations, efflux pumps, or hydrolysis by β-lactamases (9). On the basis of molecular studies, we can classify carbapenem-hydrolyzing enzymes into 4 groups: A, B, C, and D. The MBLs, which belong to group B, are enzymes that require divalent cations as cofactors for optimal enzyme activity and are inhibited by the action of a metal ion chelator. Hospital infections caused by P. aeruginosa are often difficult to eradicate because the organisms are resistant to drugs. Therefore, detection of MBL-producing P. aeruginosa is crucial to control the spread of resistance and for optimal treatment of patients, especially burn patients (10). There is no information concerning the prevalence of MBL-producing P. aeruginosa strains in Kurdistan province.

Objectives
We conducted this study to detect MBL-producing strains among P. aeruginosa isolates obtained from burn patients at Tohid hospital, which is affiliated to Kurdistan University of Medical Sciences and has a burn unit with a heavy patient turnover and extensive antibiotic use.

Materials and Methods
Between April 2009 and April 2010, we isolated and identified 100 strains of P. aeruginosa in a clinical laboratory at Tohid hospital, Sanandaj, Iran. The strains were identified as P. aeruginosa on the basis of colony morphology, gram staining results, motility, oxidase reaction, production of the pyocyanin pigment, nitrate reduction, the use of citrate and malonate as carbon sources, and the ability to grow at 5˚C and 42˚C.

3-2. Detection of MBL
Detection of MBL-producing P. aeruginosa strains was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines (11). P. aeruginosa ATCC 27853 was used as the negative control. For the doubledisk synergy test, the inoculum was prepared after emulsifying 5-6 colonies of the suspected isolate in Mueller-Hinton broth, and the turbidity was adjusted to 0.5 McFarland opacity standard. A lawn culture was obtained on Mueller-Hinton agar, and double-disk synergy test was performed.

3-3. Determination of Minimal Inhibitory Concentration
Imipenem minimal inhibitory concentration (MIC) was determined by microplate (NUNC, Denmark) broth dilution method on Mueller-Hinton agar. Zone diameter and MIC interpretive standards for breakpoints for P. aeruginosa published by CLSI were used (11).

3-4 Genotypic Detection of VIM, SIM, and GIM MBL Genes by PCR
To detect VIM, SIM, and GIM MBL genes, PCR was performed for P. aeruginosa isolates (12)

Results
In this study, we identified 100 P. aeruginosa isolates among 176 clinical specimens obtained from patients. Table 1 shows the antibiotic-resistance pattern of P. aeruginosa isolates. The isolates showed maximum resistance to ampicillin (100%), ceftazidime (94%), and ceftriaxone (89%). The next step in testing was designed to identify the MBL-producing P. aeruginosa strains. In the CLSI-MBL phenotypic test, of the 100 P. aeruginosa isolates, 22 (22%) were positive for MBL production by the double-disk synergy test (Figure 1).

4-1 Determination of MIC
The MIC of MBL-positive isolates for imipenem is shown in Table 2; among 22 MBL-positive strains, 8 were resistant. PCR detection for MBL showed that 8 strains were (18). In this study, 22% of the imipenem-resistant P. aeruginosa isolates were MBL-positive, with 8% positive for VIM1, which is by far the most prevalent MBL in Iran 20 . To our knowledge, MBLs of other families like SIM have not been detected in P. aeruginosa. The prevalence of MBL-producing P. aeruginosa differs across Iranian studies, which may be because of differences in geographic regions. Further investigation is required to gain a better understanding of the epidemiology and genetic background of MBL-producing P. aeruginosa. The uncontrolled spread of MBL producers in hospitals may hamper treatment procedures and lead to increased morbidity and mortality. Systems for regular screening should be established

Discussion
Because of its broad antimicrobial spectrum and stability against most common β-lactamases, imipenem generally represents one of the last alternatives for the treatment of nosocomial infections caused by multidrug-resistant gram-negative bacteria, particularly P. aeruginosa (13). However, the rapid spread of MBLs among major gram-negative pathogens, particularly P. aeruginosa, is an emerging threat and a matter of concern worldwide (14-16); further, MBL-carrying bacteria are known to cause recalcitrant nosocomial infections (17). MBLs of the IMP, VIM, and SIM families are frequently detected in imipenem-resistant P. aeruginosa in Iran (18)(19)(20). In our study, a total of 100 P. aeruginosa strains were isolated from hospitalized burn patients in Sanandaj, Iran, in 2010, and 22% of these strains were found to be MBL producers, which is much lower than the findings from the study conducted by Mihani  to control the spread of MBL producers, and effective infection-control programs in hospitals should be developed and implemented thoroughly. The study results demonstrate the serious therapeutic threat of the spread of MBL-producing P. aeruginosa. This number (22% of imipenem-resistant P. aeruginosa) might have been higher if other genes were included. Early detection and infection control practices are the best defense against this organism; therefore, systematic surveillance to detect MBL producers is necessary.